GleamWall
中文EN

PTIX Protagenic Therapeutics, Inc.\new

Pharmaceutical Preparations · OTC · SEC CIK 1022899 · Fiscal year ends 03/31

Financial factors as of 2026-09-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY168.9%
TTM EPS YoY138.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA155.7%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets50.8%
Debt / equity0.00x
Current ratio0.16x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.30x
Accruals ratio201.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-03-31FY20252025-03-31
Income statement
Revenue$0$0
R&D expense$901,896$376,740
SG&A expense$332,393$77,530
Operating income-$4.50M-$2.59M
Pretax income$1.37M-$3.59M
Net income$1.37M-$3.59M
EBITDA-$4.45M—
EPS (basic)0.59-0.67
EPS (diluted)0.59-0.67
Weighted avg. shares (diluted)2.33M5.37M
Banking
Net interest income-$1.50M-$1.04M
Balance sheet
Cash & equivalents$1.51M$14,531
Inventory—$1,038
Current assets$1.54M$89,093
PP&E, net$14,556$60,474
Intangibles$2.09M—
Total assets$3.65M$89,093
Current liabilities$1.03M$5.04M
Total liabilities$1.03M$5.04M
Shareholders' equity$2.62M-$4.95M
Shares outstanding1.81M5.80M
Cash flow statement
Operating cash flow-$2.81M-$1.77M
Capital expenditure$3,297—
Free cash flow-$2.81M—
Investing cash flow$629,883—
Financing cash flow$3.87M$1.81M
Depreciation & amortization$49,215—
Stock-based compensation$418,589—

Free plan shows the latest 2 periods; Pro shows all 15 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.